Primary Causes of Death in Patients with Non-Hodgkin's Lymphoma: A Retrospective Cohort Study

被引:5
作者
Mei, Mei [1 ,2 ]
Wang, Yingjun [1 ,2 ]
Song, Wenting [1 ,2 ]
Zhang, Mingzhi [1 ]
机构
[1] Zhengzhou Univ, Dept Oncol, Affiliated Hosp 1, 1 Jianshe East Rd, Zhengzhou, Henan, Peoples R China
[2] Zhengzhou Univ, Acad Med Sci, Zhengzhou, Henan, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷
基金
中国国家自然科学基金;
关键词
NHL; competing-risks regression; survival analysis; overall survival; ECOG score; cause-specific mortality; FOLLICULAR LYMPHOMA; MORTALITY; MODEL;
D O I
10.2147/CMAR.S243672
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Non-Hodgkin's lymphoma (NHL) comprises many serious hematologic malignancies from lymphocytes. The incidence of NHL is 5.1 per 100,000, with a mortality rate of 2.5 per 100,000 worldwide. However, the causes of death among patients with NHL vary. This retrospective cohort study aimed to elucidate the primary causes and specific risk factors for NHL. Patients and Methods: The study included patients who were diagnosed from January 2006 to January 2018. Grouped by sex, Ann Arbor stage, date of diagnosis, age, B symptom, NHL type, international prognostic index, and Eastern Cooperative Oncology Group (ECOG) performance score, the Log-rank test was performed, and survival curves were drawn using the Kaplan-Meier method. The competing-risks regression model was used to analyze the specific causes of death. Results: T-cell lymphoma, B symptoms and worse performance were associated with a lower survival. Mortality from NHL accounted for most and other common causes that contributed to death included circulatory and respiratory diseases. Patients diagnosed with T-cell lymphoma were more likely to die of NHL rather than other causes. Moreover, patients with B symptoms on admission were more likely to die of diseases of the circulatory system. Lastly, patients diagnosed at an earlier age suffered more from diseases of the digestive system and immune mechanism or other uncommon causes. Conclusion: Classifications of subtypes, age and occurrence of B symptoms were factors providing references for a specific cause of death owing to NHL, which might enable physicians to decrease cause-specific mortality rates.
引用
收藏
页码:3155 / 3162
页数:8
相关论文
共 50 条
  • [11] Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study
    Fallah, M.
    Liu, X.
    Ji, J.
    Forsti, A.
    Sundquist, K.
    Hemminki, K.
    ANNALS OF ONCOLOGY, 2014, 25 (10) : 2025 - 2030
  • [12] Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis
    Wang, Tong
    Gui, Wei
    Shen, Quanliang
    MEDICAL ONCOLOGY, 2010, 27 (03) : 661 - 666
  • [13] Clinicopathological and immunohistochemical profile of patients with Non-hodgkin's lymphoma
    Basharat, Shifa
    Ntidar, Bibi Hasina
    Naeem, Shaleem
    Batoo, Zufishan
    Ali, Nosheen
    Ahmad, Zahra
    RAWAL MEDICAL JOURNAL, 2019, 44 (03): : 472 - 476
  • [14] Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study
    Kamel, Mohamed Gomaa
    El-Qushayri, Amr Ehab
    Tran Quang Thach
    Nguyen Tien Huy
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) : 91 - 100
  • [15] Primary gastrointestinal non-Hodgkin’s lymphoma: clinicopathological and prognostic analysis
    Tong Wang
    Wei Gui
    Quanliang Shen
    Medical Oncology, 2010, 27 : 661 - 666
  • [16] Clinicopathological Spectrum of Hodgkin's and Non-Hodgkin's Lymphoma: A Tertiary Care Cancer Hospital Study in Pakistan
    Aslam, Wardah
    Habib, Maryam
    Aziz, Saeeda
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [17] Case studies of elderly patients with non-Hodgkin's lymphoma
    Luminari, Stefano
    Federico, Massimo
    HEMATOLOGY REPORTS, 2011, 3 : 20 - 22
  • [18] Cladribine in indolent non-Hodgkin's lymphoma
    Sigal, Darren S.
    Saven, Alan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (04) : 535 - 545
  • [19] Molecular remission and non-Hodgkin's lymphoma
    Darby, AJ
    Johnson, PWM
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (03) : 549 - 562
  • [20] Checkpoint Inhibition in Non-Hodgkin's Lymphoma
    Hess, Georg
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (11) : 662 - 672